GLP-1s Are Bigger Than Weight Loss

The Ozempic Conversation Is Missing the Point

When most people talk about GLP-1 drugs, they talk about weight. Semaglutide, tirzepatide, liraglutide — the cultural conversation has reduced these molecules to appetite suppressants for people who don’t want to diet.

That framing is doing a disservice to some genuinely fascinating science.

GLP-1 (glucagon-like peptide-1) is a hormone produced in your gut in response to food. The drugs that target its receptor were originally developed for type 2 diabetes because of GLP-1’s role in insulin secretion. Weight loss was a side effect researchers noticed and then decided to lean into.

But the receptor for GLP-1 isn’t just in your pancreas. It’s in your heart, your brain, your immune cells, and your kidneys. And that distribution is starting to tell a very different story.

The Cardiovascular Data Is Striking

The LEADER trial with liraglutide and the SUSTAIN-6 trial with semaglutide showed something that surprised even the researchers: these drugs significantly reduced major cardiovascular events — heart attack, stroke, cardiovascular death — in high-risk patients.

This wasn’t a metabolic effect from weight loss. The cardiovascular benefit showed up faster than the weight changes could account for, and it appeared even in patients who didn’t lose much weight. There’s something happening at the level of arterial inflammation, plaque stabilisation, and cardiac muscle function that goes beyond calories.

The Addiction Signal

This is where it gets genuinely strange.

Multiple observational studies and a handful of preclinical experiments are showing that GLP-1 receptor agonists reduce consumption of alcohol, nicotine, and opioids. People prescribed semaglutide for diabetes or weight loss are reporting — unsolicited — that they’re drinking less, smoking less, and feeling less pulled toward compulsive behaviours.

The mechanistic hypothesis points to the dopamine system. GLP-1 receptors are expressed in the nucleus accumbens — the brain’s reward centre — and appear to modulate the dopamine response to rewarding stimuli. Essentially, the drug may be turning down the volume on craving signals.

Clinical trials are now underway for alcohol use disorder and nicotine dependence. This could become one of the most significant developments in addiction medicine in decades.

Neurodegeneration: The Parkinson’s and Alzheimer’s Data

Researchers in Denmark noticed something curious: patients on GLP-1 drugs for diabetes had lower rates of Parkinson’s disease diagnosis than matched controls.

Follow-up preclinical work has shown GLP-1 receptor activation reduces neuroinflammation, protects dopaminergic neurons, and may slow the progression of alpha-synuclein aggregation — the hallmark of Parkinson’s pathology. A phase 2 trial with semaglutide in Parkinson’s patients is currently enrolling.

The Alzheimer’s connection is earlier-stage but follows similar logic: GLP-1 appears to reduce amyloid production and tau phosphorylation in animal models, and epidemiological data shows reduced dementia incidence in diabetic patients on GLP-1 drugs.

What This Means for How We Think About These Drugs

The weight loss narrative has done something counterproductive: it’s made GLP-1 drugs feel like a shortcut, a cheat code, a celebrity vanity treatment. That framing ignores the possibility that we’ve accidentally stumbled onto a molecule that does something important for metabolic-inflammatory-neurological health that we don’t fully understand yet.

That’s not a reason to rush out and start semaglutide. The side effect profile is real — nausea, GI disruption, potential thyroid effects, the unresolved question of muscle mass preservation during weight loss. And the long-term data simply doesn’t exist yet for healthy people using these drugs preventively.

But it is a reason to pay close attention to this space. The next five years of GLP-1 research may reframe how we think about metabolic disease, addiction, and neurodegeneration simultaneously.

That’s a bigger story than Ozempic face.